JBC Transcription and Nuclear Factor Monoclonals

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M405966200 on July 20, 2004

J. Biol. Chem., Vol. 279, Issue 39, 40445-40450, September 24, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/39/40445    most recent
M405966200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kerschbaumer, R. J.
Right arrow Articles by Scheiflinger, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kerschbaumer, R. J.
Right arrow Articles by Scheiflinger, F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

An Antibody Specific for Coagulation Factor IX Enhances the Activity of the Intrinsic Factor X-activating Complex*

Randolf J. Kerschbaumer{ddagger}, Klaudia Riedrich{ddagger}, Martina Kral{ddagger}, Katalin Varadi§, Friedrich Dorner¶, Jan Rosing||, and Friedrich Scheiflinger{ddagger}**

From the {ddagger}Pre-Clinical Product Development, Baxter BioScience, Biomedical Research Center, A-2304 Orth/Donau, Austria, §Vascular Biology, Baxter BioScience, A-1220 Vienna, Austria, Global R&D, Baxter BioScience, A-1220 Vienna, Austria, and ||Cardiovascular Research Institute Maastricht, Maastricht University, 6200MD Maastricht, The Netherlands

Received for publication, May 28, 2004 , and in revised form, July 6, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
During hemostasis the zymogen factor X (FX) is converted into its enzymatically active form factor Xa by the intrinsic FX-activating complex. This complex consists of the protease factor IXa (FIXa) that assembles, together with its cofactor, factor VIIIa, on a phospholipid surface. We have studied the functional properties of a FIXa-specific monoclonal antibody, 224AE3, which has the potential to enhance intrinsic FX activation. Binding of the antibody to FIXa improved the catalytic properties of the intrinsic FX-activating complex in two ways: (i) factor VIIIa bound to the FIXa-antibody complex with a more than 18-fold higher affinity than to FIXa, and (ii) the turnover number (kcat) of the enzyme complex increased 2- to 3-fold whereas the Km for FX remained unaffected. The ability of 224AE3 to increase the FXa-generation potential (called the "booster effect") was confirmed in factor VIII (FVIII)-depleted plasma, which was supplemented with different amounts of recombinant FVIII. In the presence of antibody 224AE3 the coagulant activity was increased 2-fold at physiological FVIII concentration and up to 15-fold at low FVIII concentrations. The booster effect that we describe demonstrates the ability of antibodies to function as an additional cofactor in an enzymatic reaction and might open up a new principle for improving the treatment of hemophilia.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
One of the key events during normal hemostasis is the conversion of the zymogen factor X (FX)1 into its enzymatically active form factor Xa (FXa) via the intrinsic coagulation pathway, a process that subsequently leads to activation of prothrombin and the formation of a fibrin clot (1). The FX-activating protease factor IXa (FIXa) assembles (together with FVIIIa as well as Ca2+ ions) on a phospholipid surface to form the intrinsic FX-activating complex (2). In this complex FVIIIa serves as a cofactor for the enzyme FIXa and increases the turnover number (kcat) of FIXa by 4 to 5 orders of magnitude (3, 4). Binding of the stoichiometric FVIIIa-FIXa complex and the substrate FX to a phospholipid surface strongly reduces the Km for the substrate (3, 4), probably because the protein-protein interactions are limited to two dimensions (5).

The physiological importance of the intrinsic FX-activating complex is well defined because the severe bleeding disorders hemophilia A and hemophilia B are characterized by very low plasma levels (< 5%) or by the absence of the pro-cofactor FVIII and the pro-enzyme FIX, respectively. Treatment of hemophilia is successfully achieved by supplementing the blood of patients with either human FVIII or human FIX. Both proteins can be derived from human plasma or produced as recombinant protein in mammalian cell culture (6, 7). Although progress in the production of coagulation factors to ensure their purity, efficacy, and viral safety has been made over the last 20 years, treatment of hemophilia is still beset with several difficulties. First, production of recombinant and plasma-derived, therapeutic coagulation factors is expensive, and products predominantly reach only the industrialized world. Second, ~30% of patients with hemophilia A and 1.5–3% of patients with hemophilia B develop antibodies against FVIII or FIX that inhibit the respective coagulation factor and complicate treatment (8–10).

Because of the clinical relevance of the intrinsic FX-activating complex, FVIII and FIX are important targets of clinical and biochemical research. A major focus of the research on the intrinsic FX-activating complex has been to overcome some of the limitations in hemophilia treatment mentioned above and to improve the production yields, reduce immunogenicity, and increase the specific activity of FVIII and FIX (11). For these purposes genetically engineered FVIII-derivatives (e.g. B-domain-deleted FVIII (12, 13)) and FIX-derivatives (e.g. pointmutated FIX (14) and chimeric FIX (15)) have been produced.

In this study a completely different approach toward improving the efficiency of FX activation by the FIXa-FVIIIa complex is described. We isolated mouse monoclonal antibodies specific for human FIXa applying hybridoma technology. When we studied the influence of these antibodies on the intrinsic FX-activating complex we discovered an antibody, named 224AE3, that binds to FIXa and enhances both the formation and the catalytic activity of the intrinsic FX-activating complex. We call this effect of the 224AE3 antibody the "booster effect."


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents—Human {alpha}-thrombin and human FIX, FIXa, FX, and FXa were purchased from Enzyme Research Laboratories (South Bend, IN). Recombinant human coagulation FVIII (rFVIII) was prepared by Baxter BioSciences (Glendale, CA). Bovine serum albumin was purchased from Calbiochem. Human FVIII-depleted plasma was obtained from Baxter BioSciences (Vienna, Austria). Nonspecific mouse IgG was purchased from Sigma. Phospholipid vesicles (60% dioleoylphosphatidylcholine, 40% dioleoylphosphatidylserine) were prepared by Baxter BioSciences (Vienna, Austria) from synthetic phospholipids (Avanti Polar Lipids, Alabaster, AL). Pathromtin SL was purchased from Dade Behring (Deerfield, IL), and Ancrod was purchased from the National Institute for Biological Standards and Control (Potters Bar, UK). Chromogenic substrate Pefachrome FXa (Pefa-5523) and the thrombin inhibitor N{alpha}-(2-naphthylsulfonylglycyl)-4-amidino-(D,L)-phenylalanine piperidide were purchased from Pentapharm (Basel, Switzerland). The fluorogenic substrate Z-Gly-Gly-Arg-AMC.HCl was purchased from Bachem (Bubendorf, Switzerland).

Hybridoma Cell Lines—Balb/c mice were immunized four times with human FIXa at intervals of 1 week. At each immunization 100 µg of antigen was applied using Al(OH)3 as adjuvant. Spleen cells were obtained 3 days after the last immunization, and hybridoma cell lines were generated according to standard procedures (16). Cell lines expressing antibodies specific for human FIXa (all of them also bound to non-activated human FIX) were subcloned four to six times to ensure that the cell line was monoclonal and stable.

Production and Purification of Antibodies and F(ab')2 and Fab Fragments—Monoclonal hybridoma cell lines were grown in RPMI 1640 medium supplemented with 5% fetal calf serum (Invitrogen) for 2–3 weeks. IgG were purified over protein G-Sepharose 4 Fast Flow (Amersham Biosciences) according to standard procedures (17). Fab fragments and F(ab')2 fragments were prepared from the purified antibody using the ImmunoPure Fab Preparation Kit and the ImmunoPure F(ab')2 Preparation Kit, respectively (Pierce) according to the manufacturer's instructions.

FXa Generation Assay—Reactions were performed in polypropylene tubes (Micronic, Lelystad, The Netherlands) in a water bath at 37 °Cas follows: 152 µl of reaction buffer containing 50 mM Tris, pH 7.4, 175 mM NaCl, 10 mM CaCl2, 0.5 mg/ml bovine serum albumin, and 13.4 µM phospholipid vesicles was prewarmed to 37 °C, and 25 µl of an antibody/FIXa mixture, 50 µl of rFVIII, and 5 µl of thrombin were added. After incubation for 2 min to activate FVIII, 23 µl of FX was added to start FXa generation. The final reaction mixture contained 8 µM phospholipid vesicles, 6 mM CaCl2, 10 n M thrombin, and concentrations of FIXa, rFVIII, FX, and antibody as described under "Results." After different time intervals, 20-µl aliquots from the reaction mixture were transferred to 230 µl of EDTA buffer containing 50 mM Tris, pH 8.3, 9 mM EDTA, and 428 mM NaCl to stop FXa formation. The amount of FXa generated was determined by mixing 210 µl of the diluted aliquots with 40 µl of a mixture containing 5 mM FXa-specific chromogenic substrate Pefa-5523 and 6 µM thrombin inhibitor N{alpha}-(2-naphthylsulfonylglycyl)-4-amidino-(D,L)-phenylalanine piperidide in a 96-well microplate and measuring the rate of chromogenic substrate conversion at 405 nm ({Delta}A/min) at 37 °C in a microplate reader (iEMS-Reader, Labsystems, Helsinki, Finland). The FXa concentration was calculated for each point in time from a calibration curve made with known amounts of FXa, and control experiments ensured that the antibody did not influence the cleavage of the chromogenic substrate Pefa-5523 by FXa.

Thrombin Generation Assay—FVIII-depleted plasma was defibrinated with 1 units/ml Ancrod, and fibrin was removed with a plastic stirring rod. 40 µl of defibrinated plasma, 10 µl of antibody, 10 µl of rFVIII, and 25 µl of Pathromtin SL were mixed in 96-well microplates (black flat bottom, Greiner, Kremsmuenster, Austria) and prewarmed at 37 °C. 15 µl of a substrate-CaCl2 mixture was added to each well to give final concentrations of 7.5 mM CaCl2 and 0.5 mM thrombin-specific fluorogenic substrate Z-Gly-Gly-Arg-AMC.HCl. The concentrations of rFVIII and antibody are described under "Results." Fluorescence (excitation, 340 nm; emission, 440 nm) was read immediately after substrate/CaCl2 addition every 30 s for 30 min in a fluorescence reader at 37 °C (SPECTRAFluor Plus Reader, Tecan, Groedig, Austria). The resultant curve shows the fluorescence units (FU) as a function of time. The tangent at each time point ({Delta}FU/min) is proportional to the thrombin concentration present in the plasma mixture. Thus, the first derivative of the resultant curve divided by a calibration factor for fluorogenic substrate conversion by thrombin ({Delta}FU/min/nM thrombin) gives a thrombin generation curve, i.e. the thrombin concentration in plasma as a function of time. The calibration factor was determined from a standard curve made with known amounts of human {alpha}-thrombin.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Features of Antibody 224AE3—We isolated a series of monoclonal antibodies that specifically bound to human FIX as well as human FIXa. In preliminary tests of a number of these antibodies in a FXa-generation assay we discovered (in addition to antibodies that inhibited or had no effect on FX activation) one monoclonal antibody, termed 224AE3, that was able to strongly increase the rate of FX activation, and we called this effect the booster effect. Western blotting and enzyme-linked immunosorbent assay experiments showed that monoclonal antibody 224AE3 specifically bound to the heavy chain (protease domain) of human FIX and FIXa and did not cross-react with other coagulation factors such as prothrombin, factor VII, FVIII, FX, or their activated counterparts. Biacore experiments revealed that this antibody bound with a very high affinity to FIXa, which was immobilized on a sensor chip. The on-rate was 1.1 x 106 M–1 s–1 but the off-rate was too low to be determined properly. Affinity thus was estimated to be in the low picomolar range (Kd < 50 pM) (data not shown).

The Effect of Antibody 224AE3 on FXa Generation—In our first set of experiments we investigated the booster effect in more detail by determining the rate of FXa generation at 33 pM FIXa and different concentrations of FVIIIa. The experiments were done either without antibody (Fig. 1A), at equimolar FIXa and antibody concentrations (33 pM, Fig. 1B), or with a large molar excess of antibody (1000 pM, Fig. 1C). The FX concentration was kept at 100 nM, which is at least 3-fold above Km (see below). FXa generation curves were linear during the initial phase of the activation reaction, indicating that FXa was formed at a constant rate. After ~3 min, the rates of FXa generation decreased, which probably reflects inactivation of FVIIIa through dissociation of the A2 domain (18). The rates of FXa formation (nM/min) were calculated from the slope of the linear part of FXa generation. Surprisingly, we found that the FXa formation rates with the antibody were higher than without antibody and that the booster effect of 224AE3 became more pronounced at low FVIII concentrations. At 2 nM rFVIIIa the FXa generation rate increased ~4-fold, whereas at 100 pM rFVIIIa (concentrations of FIXa and antibody were 33 pM), the antibody increased the rate of FXa generation ~35-fold.



View larger version (13K):
[in this window]
[in a new window]
  		FIG. 1.
The effect of antibody 224AE3 on time courses of FXa generation at different FVIII concentrations. Time courses of FXa generation were determined as described under "Experimental Procedures" at 33 pM FIXa, 100 nM FX, 8 µM phospholipid vesicles, 6 mM CaCl2, and no FVIII (), 0.1 nM FVIII ({circ}), 0.25 nM FVIII ({blacktriangleup}), 1 n M FVIII ({triangleup}), or 2 nM FVIII ({square}). Data were generated without antibody (A), with 33 pM antibody (B), and with 1000 pM antibody (C).

 
Plots of rates of FXa formation as a function of the FVIIIa concentration (Fig. 2) could be fitted to a single-site ligand-binding model (19), which enabled calculation of the FVIIIa concentration required to obtain half-maximum rates of FXa formation (Table I). This value corresponds to the apparent Kd (Kd(app)) for dissociation of the phospholipid-bound FIXa-FVIIIa complex. Binding of 224AE3 to FIXa led to an 18-fold decrease of the Kd(app), which dropped from 2.4 nM without antibody to 0.13 nM in the presence of antibody. This effect appeared to be independent of the antibody concentration because the Kd(app) at 1000 pM antibody did not differ greatly from the value obtained at 33 pM antibody.



View larger version (14K):
[in this window]
[in a new window]
  		FIG. 2.
The effect of antibody 224AE3 on FIXa-FVIIIa complex formation. FXa generation assays were performed at 33 pM FIXa, 100 pM FX, 8 µM phospholipid vesicles, 6 mM CaCl2, and different concentrations of FVIII either without antibody ({circ}) or with 33 pM antibody ({blacktriangleup}) or 1000 pM antibody ({square}). FXa formation rates were plotted as a function of the FVIII concentration. The inset shows the entire scope of the hyperbola determined without antibody. Data were fitted using the single-site ligand-binding model, and the Kd(app) and the Vmax obtained are summarized in Table I.

 


View this table:
[in this window]
[in a new window]
  		TABLE I
The effect of antibody 224AE3 on FIXa-FVIIIa complex formation and on the kinetic parameters of the intrinsic FX-activating complex

The FVIII concentration (nM) required to obtain half-maximum rates of FXa formation (Kd(app)), as well as the FXa formation rate at FVIII saturation (Vmax) were calculated by fitting the data from Fig. 2 to a single-site ligand model. The kinetic parameters (kcat and Km) of the intrinsic FX-activating complex were obtained by fitting the data presented in Fig. 4 to the Michaelis-Menten equation. The Solver function of Windows Excel was used for both fitting procedures. Results shown represent the average ± S.D. derived from three independent experiments. The catalytic efficiency (kcat/Km) was calculated from the respective averages.

 
In addition, the antibody increased the maximum rate of FXa generation at saturating FVIIIa levels (Vmax), an effect that is dependent on the antibody concentration (Table I). In the presence of equimolar amounts of antibody and FIXa, the Vmax was ~2-fold higher than without antibody. However, at very high antibody concentrations, the Vmax was the same as without antibody. To further investigate the dependence of the Vmax on the antibody concentration, the amount of antibody present in the reaction mixture was varied. In this experiment (Fig. 3A) the reaction mixture contained 33 pM FIXa, 100 nM FX, different concentrations of 224AE3 (0–2.5 nM), and FVIIIa concentrations that were at least 2.5-fold above Kd. Maximum acceleration of FXa generation (2.8-fold compared with the control experiment without 224AE3) was observed when FIXa and antibody were present in the equimolar range. At high antibody concentrations the rate of FXa formation returned to the value obtained in the absence of antibody.



View larger version (22K):
[in this window]
[in a new window]
  		FIG. 3.
The effect of varying concentrations of antibody 224AE3 or its fragments on FXa generation. FXa generation assays were performed at 33 pM FIXa, 100 nM FX, 8 µM phospholipid vesicles, 6 mM CaCl2, and 6 nM FVIII without antibody or 3 nM FVIII when different antibody or antibody fragment concentrations were added. The graphs show the FXa formation rates plotted as a function of (A) the corresponding antibody concentrations (0–2.5 nM) and (B) the corresponding F(ab')2 or Fab concentrations (0–1.0 nM).

 
Optimal enhancement of Vmax seems to occur at a FIXa: antibody ratio at which most antibody molecules have bound two FIXa molecules. In contrast, the decrease of the Kd(app) appears to be independent from such a double saturation. To prove this, we prepared monovalent Fab and divalent F(ab')2 fragments of antibody 224AE3. These fragments were used in FVIIIa-titration experiments, and at all antibody fragment concentrations tested both fragments were able to enhance the affinity of FIXa for FVIIIa to a similar extent as the antibody; the monomeric Fab fragment gave a Kd(app) of 0.25 nM, and the dimeric F(ab')2 fragment gave a Kd(app) of 0.11 nM. But at saturating FVIIIa concentrations the F(ab')2 fragment (but not the Fab fragment) increased the rate of FXa generation. As in the case of the antibody, an ~3.5-fold enhancement was observed at a molar FIXa:F(ab')2 ratio where double saturation of the dimeric fragment with FIXa can be expected (Fig. 3B).

Effect of Antibody 224AE3 on the Kinetic Parameters of Intrinsic FX Activation—To obtain more information on the influence of 224AE3 on the turnover number (kcat) of the intrinsic FX-activating complex and on the affinity of the complex for FX (Km), we performed a Michaelis-Menten kinetic analysis. Rates of FX activation were determined as a function of the FX concentration (Fig. 4) (i) at 33 pM FIXa without antibody, (ii) at equimolar antibody and FIXa concentrations (both 33 pM), and (iii) at an excess of antibody (1000 pM antibody and 33 pM FIXa), whereas FVIIIa concentrations were kept at least 2.5-fold above Kd. The maximum rate of FXa generation (Vmax) and the Km for FX were calculated by fitting the data to the Michaelis-Menten equation, and the turnover number (kcat) was obtained by dividing the Vmax by the concentration of the FIXa-FVIIIa complex (Table I). The kcat was increased 2.5-fold at equimolar concentrations of FIXa and antibody, but at high antibody concentrations the kcat returned to the value determined without antibody. The Km for FX (26 ± 3 nM) was not affected by the presence of antibody, and in all cases its value was below the physiological (plasma) FX concentration (136 nM). Michaelis-Menten kinetic analysis with the Fab and the F(ab')2 fragments of antibody 224AE3 showed that the F(ab')2 fragment, like the antibody, increased the kcat of the intrinsic FX-activating complex 3-fold (246 min–1) only when FIXa and the F(ab')2 fragment were present in the same concentration range and that the monomeric Fab fragment had no effect on the kcat (74 min–1).



View larger version (14K):
[in this window]
[in a new window]
  		FIG. 4.
Michaelis-Menten kinetic analysis of FX activation by FIXa-FVIIIa and FIXa-FVIIIa-antibody complexes. FXa-generation assays were performed at 33 pM FIXa, 8 µM phospholipid vesicles, 6 mM CaCl2, 3 nM FVIII with antibody, or 6 nM FVIII without antibody and at different FX concentrations (0–100 nM). The resultant FXa formation rates were plotted as a function of the FX concentration. Hyperbolas were obtained without antibody ({circ}), with 33 pM antibody ({blacktriangleup}), and with 1000 pM antibody ({square}). Data were fitted to the Michaelis-Menten equation, and the kcat and Km values obtained are summarized in Table I.

 
The Effect of Antibody 224AE3 in Thrombin Generation Assays—The experiments described so far show the booster effect of the procoagulant 224AE3 antibody on intrinsic FX activation in a well defined model system containing purified proteins. We used thrombin generation assays to test whether the antibody also has a beneficial effect in plasma. The thrombin generation assay probes the whole intrinsic coagulation cascade from contact activation to the formation of thrombin as well as the inactivation of activated coagulation factors by plasma protease inhibitors. All reactants were present in plasma at their physiological concentrations except FVIII, as FVIII-depleted plasma was used and rFVIII was added at known concentrations. The method applied was a modified version of the thrombin generation assay described by Hemker and Beguin (20). In our approach, all reactants, including a fluorogenic thrombin substrate, were present in the reaction mixture, and after initiation of coagulation fluorescence was measured every 30 s. The first derivative of these curves, divided by the calibration factor for fluorogenic substrate conversion by thrombin, yielded the thrombin concentration in plasma as a function of time (Fig. 5A). After a lag period, there was a burst of thrombin formation followed by inhibition of thrombin by antithrombin and {alpha}2-macroglobulin. The time required to reach the maximum thrombin concentration (hereafter referred to as the peak time) was strongly dependent on the FVIII-concentration and became shorter at increasing FVIII concentrations. This is consistent with the clotting time in the one-stage clotting assay and enabled us to quantify the FVIII activity in plasma from thrombin generation curves. Recombinant FVIII was added to FVIII-depleted plasma to give rFVIII concentrations of 0 to 1000 milliunits/ml (corresponding to 0–100% rFVIII activity), and thrombin generation assays were performed in the various plasma mixtures. The peak time appeared to be a linear function of the logarithm of the FVIII concentration present in plasma (linear range of the calibration curve from 0.1 to 50 milliunits/ml). Extrapolation of the calibration curve enabled estimation of the residual FVIII activity in FVIII-depleted plasma. A corrected calibration curve was obtained by iterative correction of the calibration curve for the residual FVIII activity (Fig. 5B). Thus, we calculated that FVIII-depleted plasma had a residual FVIII activity of 0.1 milliunits/ml.



View larger version (24K):
[in this window]
[in a new window]
  		FIG. 5.
Thrombin generation in plasma containing different FVIII concentrations. A, thrombin generation curves were determined as described under "Experimental Procedures" at rFVIII concentrations (milliunits/ml) indicated in the figure. B, calibration curve representing peak times of thrombin generation depicted as a function of the log of the corresponding FVIII concentrations (log milliunits/ml) obtained after correction by five iteration rounds as described under "Experimental Procedures."

 
Thrombin generation assays at different FVIII concentrations were repeated with antibody 224AE3 added to the plasma mixture. In the presence of antibody peak times were shorter than that in the control experiment in which no antibody had been added to plasma. The most pronounced effects were obtained at 45–60 nM antibody, the concentration range where double saturation of antibody (2 FIX per antibody) can be expected as the FIX concentration in human plasma is 90 nM. Using the calibration curve presented in Fig. 5B, the calculated FVIII activities were 2- to 15-fold higher than the actual FVIII concentrations present in the plasma mixture when 60 nM antibody were added. These increased FVIII activities reflect an enhanced thrombin formation potential or coagulant activity mediated by 224AE3. The enhancement of the coagulant activity with antibody (booster effects) at the different FVIII concentrations is depicted in Fig. 6. At 1000 milliunits/ml FVIII, the antibody enhanced the coagulant activity 2-fold, but the booster effect became gradually more pronounced at lower FVIII concentrations. At a FVIII concentration of 10 milliunits/ml the peak time measured corresponded to ~60 milliunits/ml FVIII. Below 1% FVIII (the region of severe hemophilia A) the presence of antibody increased the coagulant activity up to 15-fold. Thrombin generation assays were repeated with nonspecific mouse IgG, which had no influence on thrombin generation (data not shown).



View larger version (26K):
[in this window]
[in a new window]
  		FIG. 6.
Effect of antibody 224AE3 on the coagulant activity (determined in FVIII-depleted plasma supplemented with different FVIII concentrations). Thrombin generation assays were performed as described under "Experimental Procedures" in FVIII-depleted plasma containing 60 nM 224AE3 and supplemented with different FVIII concentrations. The resultant peak times were used to determine the FVIII activity applying the calibration curve presented in Fig. 5B. The value for the booster effect (y axis) represents the enhancement of the FVIII-activity (coagulant activity) as a function of the total FVIII concentration (0.1 milliunits/ml residual FVIII concentration and rFVIII added) present in the plasma mixture (x axis). The graph shows an average of three independent determinations. Error bars depict the highest and the lowest booster factor determined.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
FVIIIa functions as a cofactor of FIXa, which depending on the assay conditions increases the rate of FXa formation ~20,000- to 200,000-fold (3, 4). The exact mechanism by which FVIIIa enhances the catalytic activity of FIXa toward FX is still unknown. It is generally believed that FVIIIa has three functions within the intrinsic FX-activating complex: (i) FVIIIa stabilizes a conformation of FIXa that has strongly increased protease activity toward FX, (ii) FVIIIa acts as a receptor for FIXa on activated platelets (2), which in vivo provide the procoagulant phospholipid surface (21), and (iii) more recent data indicate that FVIIIa directs the cleavage sites in FX toward the active site of FIXa (22). We identified a murine monoclonal antibody, 224AE3, that specifically binds to human FIXa and that enhances the catalytic activity of the FVIIIa-FIXa-Ca2+-phospholipid complex. Kinetic analysis revealed that the antibody had two different modes of action; first it increased the affinity of FIXa for FVIIIa ~18-fold, and second it caused a 2.5-fold increase of the kcat of FX activation. Overall, at low FIXa and FVIIIa concentrations (FVIIIa and FIXa in picomolar range) the antibody enhanced the rate of activation of FX to FXa more than 30-fold.

Plasma assays confirmed the results obtained in the model systems and verified the potential of what we called the booster effect of the antibody 224AE3. Assays in FVIII-depleted plasma, which was supplemented with known amounts of rFVIII, showed that the procoagulant activity was enhanced up to 15-fold in the presence of the antibody. Again, the booster effect became more pronounced at low FVIII concentrations. The kinetic data indicate that at high FVIII concentrations the booster effect of the antibody is primarily caused by a 2.5-fold increase in the kcat of FX activation, which is in line with the 2-fold enhancement of FVIII activity at physiologic FVIII concentrations. At lower FVIII concentrations the enhanced affinity of FIXa for FVIIIa becomes more important because lower FVIII concentrations are required to saturate FIXa bound to 224AE3 than to saturate FIXa without antibody.

The FXa-generation experiments show that our antibody does not influence the loss of FVIII activity observed during FX activation in model systems. In the presence as well as absence of antibody, the rate of FXa generation decreases after ~3 min. Thus, the antibody does not prolong FXa generation, but it increases the initial rate of FX activation. Inactivation of FVIII in this assay is probably by dissociation of the A2 domain (18). We also concluded from the thrombin generation curves that 224AE3 only amplifies the activity of the intrinsic FX-activating complex and does not influence other reactions of the intrinsic coagulation cascade. The shapes of the curves are the same with and without antibody and show a thrombin burst and inhibition of the generated thrombin after the peak has been reached. Thus, neither the activation of coagulation factors other than FX nor their inhibition or inactivation seems to be affected by 224AE3.

Antibodies are known to be versatile molecules that have properties beyond their classic immunological function and have been shown to be able to modify the biochemical and biological properties of their target proteins. For instance, antibodies with catalytic properties have been described that serve as enzymes. Numerous inhibitory antibodies have been identified that block enzymes, neutralize cytokines, or act as receptor antagonists. However, antibodies that have agonistic properties are relatively rare but have been generated for some receptors (23–26). The antibody 224AE3, which was isolated by conventional hybridoma technology, shows a new feature as it functions as an additional cofactor in an enzyme reaction within the coagulation cascade. The molecular mechanism of action of this antibody is unknown, but our data suggest that this antibody stabilizes a conformation of the protease FIXa, which has an increased affinity for its cofactor FVIIIa. The enhanced FIXa-FVIIIa interaction (effect on Kd(app)) is obtained when FIXa is saturated with antibody or its Fab or F(ab')2 fragment and does not alter when the antibody is present in large molar excess. However, the increase of the turnover number (kcat) is lost at high antibody or F(ab')2 fragment concentrations and is not observed in experiments with the monomeric Fab fragment. This indicates that the effect of the antibody on the kcat requires a double saturation of the antibody (2 moles of FIXa per mole of antibody), and thus the cross linkage of two FX-activating complexes.

Although the practical relevance of antibodies that enhance intrinsic FXa generation and that promote coagulation and clot formation has to be proven, the booster effect we describe might open up a new principle for improving treatment of hemophilia. A human antibody, an antibody derivative, or an antibody mimetic that shows the same features as 224AE3 could be developed and used as a specific enhancer of coagulation in patients with hemophilia.


   FOOTNOTES
 
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

** To whom correspondence should be addressed: Baxter BioScience, Biomedical Research Center, Uferstrasse 15, 2304 Orth/Donau, Austria. Tel.: 43-1-20100-3410; Fax: 43-1-20100-4679; E-mail: scheiff{at}baxter.com.

1 The abbreviations used are: FX, factor X; FXa, factor Xa; rFVIII, recombinant factor VIII; FU, fluorescence units. Back


   ACKNOWLEDGMENTS
 
We thank Elise Langdon-Neuner for expert editing.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Mann, K. G. (1999) Thromb. Haemostasis 82, 165–174[Medline] [Order article via Infotrieve]
  2. van Dieijen, G., van Rijn, J. L., Govers-Riemslag, J. W., Hemker, H. C., and Rosing, J. (1985) Thromb. Haemostasis 53, 396–400[Medline] [Order article via Infotrieve]
  3. van Dieijen, G., Tans, G., Rosing, J., and Hemker, H. C. (1981) J. Biol. Chem. 256, 3433–3442[Abstract/Free Full Text]
  4. Rawala-Sheikh, R., Ahmad, S. S., Ashby, B., and Walsh, P. N. (1990) Biochemistry 29, 2606–2611[CrossRef][Medline] [Order article via Infotrieve]
  5. Mann, K. G., Nesheim, M. E., Church, W. R., Haley, P., and Krishnaswamy, S. (1990) Blood 76, 1–16[Abstract/Free Full Text]
  6. Kaufman, R. J., Wasley, L. C., Furie, B. C., Furie, B., and Shoemaker, C. B. (1986) J. Biol. Chem. 261, 9622–9628[Abstract/Free Full Text]
  7. Kaufman, R. J., Wasley, L. C., and Dorner, A. J. (1988) J. Biol. Chem. 263, 6352–6362[Abstract/Free Full Text]
  8. Brettler, D. B. (1996) Baillieres Clin. Haematol. 9, 319–329[CrossRef][Medline] [Order article via Infotrieve]
  9. Penner, J. A. (2001) Haemophilia 7, 103–108[Medline] [Order article via Infotrieve]
  10. Bolton-Maggs, P. H., and Pasi, K. J. (2003) Lancet 361, 1801–1809[CrossRef][Medline] [Order article via Infotrieve]
  11. Kaufman, R. J., and Pipe, S. W. (1998) Haemophilia 4, 370–379[CrossRef][Medline] [Order article via Infotrieve]
  12. Toole, J. J., Pittman, D. D., Orr, E. C., Murtha, P., Wasley, L. C., and Kaufman, R. J. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 5939–5942[Abstract/Free Full Text]
  13. Donath, M. J., de Laaf, R. T., and Biessels, P. T. (1995) Biochem. J. 312, 49–55
  14. Chang, J., Jin, J., Lollar, P., Bode, W., Brandstetter, H., Hamaguchi, N., Straight, D. L., and Stafford, D. W. (1998) J. Biol. Chem. 273, 12089–12094[Abstract/Free Full Text]
  15. Chang, J. Y., Monroe, D. M., Stafford, D. W., Brinkhous, K. M., and Roberts, H. R. (1997) J. Clin. Investig. 100, 886–892[Medline] [Order article via Infotrieve]
  16. Köhler, G., and Milstein, C. (1975) Nature 256, 495–497[CrossRef][Medline] [Order article via Infotrieve]
  17. Jungbauer, A., Tauer, C., Reiter, M., Purtscher, M., Wenisch, E., Steindl, F., Buchacher, A., and Katinger H. (1989) J. Chromatogr. 476, 257–268[CrossRef][Medline] [Order article via Infotrieve]
  18. Lollar, P., and Parker, C. G. (1990) J. Biol. Chem. 265, 1688–1692[Abstract/Free Full Text]
  19. Jenkins, P. V., Freas, J., Schmidt, K. M., Zhou, Q., and Fay, P. J. (2002) Blood 100, 501–508[Abstract/Free Full Text]
  20. Hemker, H. C., and Beguin, S. (1995) Thromb. Haemostasis 74, 134–138[Medline] [Order article via Infotrieve]
  21. Rosing, J., van Rijn, J. L., Bevers, E. M., van Dieijen, G., Comfurius, P., and Zwaal, R. F. (1985) Blood 65, 319–332[Abstract/Free Full Text]
  22. Lapan, K. A., and Fay, P. J. (1997) J. Biol. Chem. 272, 2082–2088[Abstract/Free Full Text]
  23. Deng, B., Banu, N., Malloy, B., Hass, P., Wang, J. F., Cavacini, L., Eaton, D., and Avraham, H. (1998) Blood 92, 1981–1988[Abstract/Free Full Text]
  24. Mace, G., Blanpied, C., Emorine, L. J., Druet, P., and Dietrich, G. (1999) J. Biol. Chem. 274, 20079–20082[Abstract/Free Full Text]
  25. Ando, T., Latif, R., Pritsker, A., Moran, T., Nagayama, Y., and Davies, T. F. (2002) J. Clin. Investig. 110, 1667–1674[CrossRef][Medline] [Order article via Infotrieve]
  26. Khaldoyanidi, S., Karakhanova, S., Sleeman, J., Herrlich, P., and Ponta, H. (2002) Blood 99, 3955–3961[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/39/40445    most recent
M405966200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kerschbaumer, R. J.
Right arrow Articles by Scheiflinger, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kerschbaumer, R. J.
Right arrow Articles by Scheiflinger, F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.